Application of physiology-based pharmacokinetic and pharmacodynamic modeling to individualized target-controlled propofol infusions

This study compared the ability of the physiology-based pharmacokinetic (PBPK) model with that of compartmental models used in propofol infusion devices to predict the pharmacokinetics and pharmacodynamics of propofol in various patient groups (children, pregnant women, young men, normal weight adults, and obese adults). With a PBPK model, loss of consciousness (LOC) and recovery of consciousness (ROC) corresponded to a narrow range of brain tissue concentrations (2.2–4.0 mg/L). With the compartmental models, predicted effect concentrations were also within a narrow range at LOC, but were outside the range at ROC. In individuals of normal weight, coefficients of variation (CV) of the predicted brain or effect concentrations at LOC were in a similar range—between 18% and 32%. In obese individuals, however, interindividual CV values for brain or effect concentrations were 41% (PBPK) and 93% (compartmental). This comparison suggests the increased flexibility of PBPK models over compartmental models, the latter of which rely heavily on the patient group from which the model was derived. The incorporation of PBPK models may provide target-controlled infusions with enhanced ability to predict response in a wide variety of patients.

[1]  M. Pellegrini,et al.  Effects of fentanyl, alfentanil, remifentanil and sufentanil on loss of consciousness and bispectral index during propofol induction of anaesthesia. , 2001, British journal of anaesthesia.

[2]  S. Blackburn Maternal, Fetal, and Neonatal Physiology: A Clinical Perspective , 1992 .

[3]  Walter Schmitt,et al.  A physiological model for the estimation of the fraction dose absorbed in humans. , 2004, Journal of medicinal chemistry.

[4]  Malcolm Rowland,et al.  Physiologically based pharmacokinetics in Drug Development and Regulatory Science: A workshop report (Georgetown University, Washington, DC, May 29–30, 2002) , 2004, AAPS PharmSci.

[5]  David G Levitt,et al.  Human physiologically based pharmacokinetic model for propofol , 2005, BMC anesthesiology.

[6]  M. Priston,et al.  Pharmacokinetics of Propofol Infusions in Critically Ill Neonates, Infants, and Children in an Intensive Care Unit , 2002, Anesthesiology.

[7]  Dale Hattis,et al.  Physiologically Based Pharmacokinetic (PBPK) Modeling of Caffeine and Theophylline in Neonates and Adults: Implications for Assessing Children's Risks from Environmental Agents , 2004, Journal of toxicology and environmental health. Part A.

[8]  R. Meuli,et al.  Brain perfusion in children: evolution with age assessed by quantitative perfusion computed tomography. , 2004, Pediatrics.

[9]  Meindert Danhof,et al.  Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery. , 2002, British journal of clinical pharmacology.

[10]  R. Farinotti,et al.  Propofol Infusion for Maintenance of Anesthesia in Morbidly Obese Patients Receiving Nitrous Oxide A Clinical and Pharmacokinetic Study , 1993, Anesthesiology.

[11]  P. Sebel,et al.  Recovery of Consciousness after Thiopental or Propofol: Bispectral Index and the Isolated Forearm Technique , 1997, Anesthesiology.

[12]  T. Kazama,et al.  Comparison of Predicted Induction Dose with Predetermined Physiologic Characteristics of Patients and With Pharmacokinetic Models Incorporating those Characteristics as Covariates , 2003, Anesthesiology.

[13]  T. Bouillon,et al.  Does size matter? , 1998, Anesthesiology.

[14]  R. Verbeeck,et al.  Propofol Pharmacokinetics in Children With Biliary Atresia , 1995 .

[15]  J. Kanto,et al.  Propofol as an induction agent in children: pain on injection and pharmacokinetics , 1989, Acta anaesthesiologica Scandinavica.

[16]  W. Mi,et al.  Performance of bispectral index and auditory evoked potential monitors in detecting loss of consciousness during anaesthetic induction with propofol with and without fentanyl , 2004, European journal of anaesthesiology.

[17]  Malcolm Rowland,et al.  Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002). , 2004, AAPS pharmSci.

[18]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[19]  E. Gepts,et al.  Disposition of Propofol Administered as Constant Rate Intravenous Infusions in Humans , 1987, Anesthesia and analgesia.

[20]  C. Saint-Maurice,et al.  Pharmacokinetics of propofol in young children after a single dose. , 1989, British journal of anaesthesia.

[21]  G. Kenny,et al.  'Paedfusor' pharmacokinetic data set. , 2005, British journal of anaesthesia.

[22]  H F Nicodemus,et al.  The Pharmacokinetics of Propofol in Children Using Three Different Data Analysis Approaches , 1994, Anesthesiology.

[23]  E. Olofsen,et al.  Mixed-effects Modeling of the Influence of Alfentanil on Propofol Pharmacokinetics , 2004, Anesthesiology.

[24]  A. Lam,et al.  Propofol: Relation between Brain Concentrations, Electroencephalogram, Middle Cerebral Artery Blood Flow Velocity, and Cerebral Oxygen Extraction during Induction of Anesthesia , 2002, Anesthesiology.

[25]  J. Levron,et al.  Performance of Target-controlled Sufentanil Infusion in Obese Patients , 2003, Anesthesiology.

[26]  P. Sebel,et al.  Women emerge from general anesthesia with propofol/alfentanil/nitrous oxide faster than men. , 1999, Anesthesiology.

[27]  A. Vandesteene,et al.  Propofol infusion for induction and maintenance of anaesthesia in patients with end-stage renal disease. , 1998, British journal of anaesthesia.

[28]  W. Stigelman,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .

[29]  T. Kazama,et al.  Investigation of Effective Anesthesia Induction Doses Using a Wide Range of Infusion Rates with Undiluted and Diluted Propofol , 2000, Anesthesiology.

[30]  M. White,et al.  Accuracy of the 'Paedfusor' in children undergoing cardiac surgery or catheterization. , 2003, British journal of anaesthesia.

[31]  I. Murat,et al.  Pharmacokinetics of Propofol after a Single Dose in Children Aged 1–3 Years with Minor Burns: Comparison of Three Data Analysis Approaches , 1996, Anesthesiology.

[32]  Fernando R Altermatt,et al.  Estimation of the Plasma Effect Site Equilibration Rate Constant (ke0) of Propofol in Children Using the Time to Peak Effect: Comparison with Adults , 2004, Anesthesiology.

[33]  Patrick Poulin,et al.  Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. , 2003, Toxicology letters.

[34]  G. Kenny,et al.  Propofol sparing effect of remifentanil using closed-loop anaesthesia. , 2003, British journal of anaesthesia.

[35]  Walter Schmitt,et al.  PK-Sim®: a physiologically based pharmacokinetic ‘whole-body’ model , 2003 .

[36]  A. Burm,et al.  Performance of Computer-Controlled Infusion of Propofol: An Evaluation of Five Pharmacokinetic Parameter Sets , 1995, Anesthesia and analgesia.

[37]  A. Casati,et al.  Anesthesia in the obese patient: pharmacokinetic considerations. , 2005, Journal of clinical anesthesia.

[38]  R. Jones,et al.  Pharmacokinetics of propofol in children. , 1990, British journal of anaesthesia.

[39]  N. Morton,et al.  Pharmacokinetic model driven infusion of propofol in children. , 1991, British journal of anaesthesia.

[40]  H. Wulf,et al.  Risk factors for bacterial catheter colonization in regional anaesthesia , 2005, BMC anesthesiology.

[41]  D. Dennis,et al.  Precision and bias of target controlled propofol infusion for sedation. , 2005, British journal of anaesthesia.

[42]  S. Shafer,et al.  The Influence of Method of Administration and Covariates on the Pharmacokinetics of Propofol in Adult Volunteers , 1998, Anesthesiology.